Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 6Phase 3 4Phase 1 3Phase NA 1Phase 4 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1

Conditions

Arthritis, Rheumatoid 2Spondylitis, Ankylosing 1Lymphoma, Non-Hodgkin 1

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Has results × tocilizumab × Clear all
NCT05171647 2026-05-07

SUNMO

Hoffmann-La Roche

Phase 3 Active not recruiting
208 enrolled 12 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT02046603 2018-12-07

ACT-MOVE

Hoffmann-La Roche

Phase 3 Completed
162 enrolled 30 charts

Arthritis, Rheumatoid

NCT00883753 2014-08-06

An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy

Hoffmann-La Roche

Phase 3 Completed
934 enrolled 40 charts

Arthritis, Rheumatoid

NCT01209689 2013-01-17

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

Hoffmann-La Roche

Phase 3 Terminated
113 enrolled 7 charts

Spondylitis, Ankylosing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡